10-Q: CNBX Pharmaceuticals Reports Q2 2024 Results: Revenue Increases but Going Concern Concerns Remain

CNBX Pharmaceuticals reports increased revenue for Q2 2024 but faces ongoing concerns about its ability to continue as a going concern due to accumulated losses and limited cash resources.

Summary

• CNBX Pharmaceuticals Inc. reported its financial results for the second quarter of fiscal year 2024, ending February 29, 2024.
• The company generated revenues of $40,637 for the three months ended February 29, 2024, and $130,074 for the six months ended February 29, 2024, primarily from lab and development services.
• Operating expenses for the three months ended February 29, 2024, were $240,845, and $490,832 for the six months ended February 29, 2024.
• The company incurred a net loss of $325,459 for the three months ended February 29, 2024, and $503,982 for the six months ended February 29, 2024.
• As of February 29, 2024, CNBX had $37,142 in cash and cash equivalents.
• The company's independent auditors have expressed concerns about its ability to continue as a going concern due to cumulative losses of $24,763,184 since inception.
• CNBX is focused on developing cannabinoid-based products, including Cannabics SR for cancer anorexia-cachexia syndrome (CACS) and RCC-33 for colorectal cancer.
• The company plans to launch Phase I/II(a) clinical studies in 2024 for Cannabics SR and RCC-33, but lacks sufficient funds to complete the Phase I/II(a) study.
• The company is seeking strategic partnerships and licensing arrangements to commercialize its drug candidates.
• CNBX realized all of its fixed assets in consideration of $113,972 and recorded a capital loss of $123,711.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While revenue increased and losses decreased, the going concern warning and limited cash raise significant concerns. The company's future depends on successful clinical trials and securing additional funding.

Positives

• The company generated revenues of $130,074 for the six months ended February 29, 2024, compared to no revenue for the same period in the previous year.
• The net loss decreased significantly to $503,982 for the six months ended February 29, 2024, compared to $2,981,990 for the six months ended February 28, 2023.
• The company is progressing towards clinical trials for its lead drug candidates, Cannabics SR and RCC-33.
• Operating expenses decreased by $105,968 for the six months ended February 29, 2024, compared to the six months ended February 28, 2023.

Negatives

• The company has a limited amount of cash on hand, with only $37,142 in cash and cash equivalents as of February 29, 2024.
• The company's auditors have raised concerns about its ability to continue as a going concern.
• The company has incurred cumulative losses of $24,763,184 since inception.
• The company needs to raise additional capital to fund its operations and clinical trials.
• The company recorded a capital loss of $123,711 from the realization of fixed assets.

Risks

• The company's ability to continue as a going concern is uncertain due to its limited cash resources and accumulated losses.
• The company's success depends on its ability to generate revenues, raise investment capital, and successfully develop and implement its business plan.
• The company faces risks associated with the development and commercialization of pharmaceutical products, including regulatory approvals, clinical trial outcomes, and market acceptance.
• The company's reliance on strategic partnerships and licensing arrangements for commercialization exposes it to risks related to finding suitable partners and negotiating favorable terms.
• The company's intellectual property may not be adequately protected, and it may face challenges from competitors.
• The company does not have sufficient funds to complete the Phase I/II(a) study.

Future Outlook

CNBX Pharmaceuticals plans to advance its drug candidates through clinical studies, including Phase I/II(a) trials for Cannabics SR and RCC-33 in 2024. The company intends to seek strategic partnerships and licensing arrangements to commercialize its products. However, the company's ability to execute its plans depends on securing additional funding and achieving positive clinical trial outcomes.

Industry Context

CNBX Pharmaceuticals operates in the biopharmaceutical industry, focusing on the development of cannabinoid-based products for cancer treatment. The company's research and development efforts align with the growing interest in the therapeutic potential of cannabinoids in oncology. The market for cancer therapies is highly competitive, with numerous companies developing novel treatments. CNBX faces competition from established pharmaceutical companies and other biotechnology firms in the cannabinoid space.

Comparison to Industry Standards

• It is difficult to compare CNBX's results directly to industry standards due to its early stage of development and focus on cannabinoid-based therapies.
• Many pharmaceutical companies in the oncology space are focused on developing targeted therapies and immunotherapies, while CNBX is pursuing a cannabinoid-based approach.
• Companies like GW Pharmaceuticals (now Jazz Pharmaceuticals) have successfully developed and commercialized cannabinoid-based drugs, demonstrating the potential of this therapeutic area.
• However, CNBX's financial position and limited cash resources pose a challenge compared to larger, more established companies in the industry.
• The company's success will depend on its ability to differentiate its products and demonstrate clinical efficacy in its target indications.

Related Party Transactions

• During the six months ending February 29, 2024, the Company paid $50,979 in salaries expenses, including socials benefits, to two directors, compared to $6,950 for the for the six months ending February 28, 2023.
• During the six months ending February 29, 2024, the Company recorded a non-cash expense of $69,950 in share-based payment, to the company chairman compared to $110,530 for the six months ending February 28, 2023.
• As of February 29, 2024, the Company had a balance outstanding payable to two directors: Gabriel Yariv and Eyal Barad in the total of $774,839 compared to $424,580 for the six months ending February 28, 2023.
• The Company had a balance outstanding on February 29, 2024 and at February 28, 2023 of $223,645 payable to Cannabics, Inc.

Stakeholder Impact

• Shareholders face uncertainty due to the company's going concern warning and need for additional funding.
• Employees' job security is at risk due to the company's financial challenges.
• Customers (potential patients) may benefit from the development of new cannabinoid-based therapies, but the timeline for commercialization is uncertain.
• Suppliers and creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• Conduct preclinical studies to establish the safety and efficacy of RCC-33.
• Prepare for and launch Phase I/II(a) clinical studies for Cannabics SR and RCC-33 in 2024.
• Submit an IND to the FDA for RCC-33.
• Identify potential contract research organizations and clinical trial centers.
• Seek strategic partnerships and licensing arrangements to commercialize drug candidates.
• Continue research and development efforts for other drug candidates in the pipeline.

Key Dates

Keywords

pharmaceuticals, cannabinoids, clinical trials, colorectal cancer, cancer, revenue, loss, going concern, financial results, CNBX